Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Open accessThe DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Abstract
Blockade of the checkpoint inhibitor programmed death 1 (PD1) has demonstrated remarkable success in the clinic for the treatment of cancer; however, a majority of tumors are resistant to anti-PD1 monotherapy. Numerous ongoing clinical combination therapy studies will likely reveal additional therapeutics that complement anti-PD1 blockade. Recent studies found that immunogenic cell death (ICD) improves T cell responses against different tumors, thus indicating that ICD may further augment antitumor immunity elicited by anti-PD1. Here, we observed antitumor activity following combinatorial therapy with anti-PD1 Ab and the cyclin-dependent kinase inhibitor dinaciclib in immunocompetent mouse tumor models. Dinaciclib induced a type I IFN gene signature within the tumor, leading us to hypothesize that dinaciclib potentiates the effects of anti-PD1 by eliciting ICD. Indeed, tumor cells treated with dinaciclib showed the hallmarks of ICD including surface calreticulin expression and release of high mobility group box 1 (HMGB1) and ATP. Mice treated with both anti-PD1 and dinaciclib showed increased T cell infiltration and DC activation within the tumor, indicating that this combination improves the overall quality of the immune response generated. These findings identify a potential mechanism for the observed benefit of combining dinaciclib and anti-PD1, in which dinaciclib induces ICD, thereby converting the tumor cell into an endogenous vaccine and boosting the effects of anti-PD1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“dinaciclib promotes immunogenic cell death (ICD) along with robust type I IFN signaling (and despite PD-L1 upregulation in this setting) in mouse models of colorectal cancer (CRC), ultimately favoring dendritic cell (DC) activation and recruitment of CD8 + T cells that can be actioned with ICIs specific for PD-1”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Hossain et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Cited by
Items 101–200 of 218
Oncolytic virus and immunogenic cell death in cancer therapy
Cao, G., Ding, C., Dai, J., & Qiu, X. (2025) · Tumour Virus Research · doi:10.1016/j.tvr.2025.200333 · Cited by 27
Zhang, B., Li, N., Gao, J., Zhao, Y., Jiang, J., Xie, S., Zhang, C., Zhang, Q., Liu, L., Wang, Z., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02974-4 · Cited by 24
“To evaluate the treatment effects of FAK inhibition alone, we began with cell-killing tests in ovarian cancer, as disease development positively correlates with FAK function.”
BackgroundImmunogenic cell death inducers for cancer therapy: An emerging focus on natural products
Zhang, L., Zhang, D.-J., Shi, J.-X., Huang, M., Yu, J.-M., Chen, X.-J., Xiao, W., Zou, L., & Lu, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155828 · Cited by 23
Zhou, Z., Lei, J., Fang, J., Chen, P., Zhou, J., Wang, H., Sun, Z., Chen, Y., & Yin, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112637 · Cited by 28
Xu, T., Wang, Z., Liu, J., Wang, G., Zhou, D., Du, Y., Li, X., Xia, Y., & Gao, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.820696 · Cited by 24
An Overview of CDK Enzyme Inhibitors in Cancer Therapy
Mounika, P., Gurupadayya, B., Kumar, H. Y., & Bannimath, N. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230320144713 · Cited by 25
Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer
Wang, Y., Pattarayan, D., Huang, H., Zhao, Y., Li, S., Wang, Y., Zhang, M., Li, S., & Yang, D. (2024) · Nature Communications · doi:10.1038/s41467-024-47433-y · Cited by 24
Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia
Yun, H. D., Schirm, D. K., Felices, M., Miller, J. S., & Eckfeldt, C. E. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000064 · Cited by 19
“Dinaciclib has been shown to influence the recognition and killing of cancer cells by the immune system, making it an attractive candidate for combined targeted and immune therapy for AML.3 Natural killer (NK) cells can induce a remission in 30% to 50% of patients with chemotherapy-refractory AML.4-6 NK cells respond…”
BackgroundPromotion of ICD via Nanotechnology
Qin, Y., Zhang, H., Li, Y., Xie, T., Yan, S., Wang, J., Qu, J., Ouyang, F., Lv, S., Guo, Z., et al. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300093 · Cited by 18
Cui, J. N., Xu, H., Shi, J., Fang, K., Liang, D., Liu, F., Wang, J., Xie, C., Xia, Z., 孟松树, et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01180-7 · Cited by 21
“Of note, some ICD inducers can function in synergy with other types of immunotherapy, such as immune checkpoint inhibitors therapy to potentiate their effectiveness [6].”
BackgroundImmunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer
Wang, D., Cong, J., Fu, B., Zheng, X., Sun, R., Tian, Z., & Wei, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.043 · Cited by 20
Yang, Y., Zheng, P., Duan, B., Yang, Y., Zheng, X. W., Li, W., Liu, Q., Hu, Y., & Ma, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.060 · Cited by 19
cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer
Ge, H., Dan, Q., & Yang, Y. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009623666221115095114 · Cited by 19
“Chemotherapy drugs can change the local immune state and improve anti-cancer immunity [51-53].”
BackgroundTargeting CDK2 to combat drug resistance in cancer therapy
Kasirzadeh, S., Lenjisa, J. L., & Wang, S. (2024) · Future Oncology · doi:10.1080/14796694.2024.2416382 · Cited by 19
Huang, Z., & Hu, H. (2021) · Molecules · doi:10.3390/molecules26020511 · Cited by 17
Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy
Wu, W., Yu, S., & Yu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188842 · Cited by 16
Khalil, R., Green, R. J., Sivakumar, K., Varandani, P., Bharadwaj, S. N., Mohapatra, S. S., & Mohapatra, S. (2023) · Cancers · doi:10.3390/cancers15123089 · Cited by 14
“Myeloid progenitor cells were isolated from the femurs of C57BL/6 mice as described previously [37].”
MethodUnique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints
Cannon, A. C., Budagyan, K., Uribe‐Alvarez, C., Kurimchak, A., Araiza‐Olivera, D., Cai, K. Q., Peri, S., Zhou, Y., Duncan, J. S., & Chernoff, J. (2024) · Oncogene · doi:10.1038/s41388-024-02947-z · Cited by 15
CDK9 inhibition as an effective therapy for small cell lung cancer
Capuccino, L. V., Kleitke, T., Szokol, B., Svajda, L., Martín, F., Bonechi, F., Krekó, M., Azami, S., Montinaro, A., Wang, Y., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06724-4 · Cited by 20
“All media were supplemented with the antibiotic Primocin (Invivogen, San Diego, CA, USA, cat# ant-pm-1).”
BackgroundMethodTargeting CDK2 and other novel cell cycle targets for breast cancer therapy
Chen, M., Luo, L., Massoumi, N. L., & Keyomarsi, K. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2537412 · Cited by 15
“Similarly, when the pan-CDK inhibitor Dinaciclib is combined with anti-PD-1 therapy, it helps overcome tumor-induced immunosuppressive mechanisms, allowing the immune system to mount a more effective anti-tumor response [150].”
Tseng, L., Lau, K.-Y., Chen, J., Chu, P., Huang, T., Lee, C., Wang, W., Chang, Y.-Y., Huang, C., Huang, C., et al. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113652 · Cited by 14
Jiang, S., Dong, Y., Wang, J., Zhang, X., Liu, W., Wei, Y., Zhou, H., Shen, L., Yang, J., & Zhu, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1207061 · Cited by 15
“Alissa Chackerian’s team suggested that ICD can be induced by dinaciclib and enhance anti-PD1-mediated tumor suppression (38).”
BackgroundZhang, Y., Zhao, H., Deng, W., Lai, J., Sang, K., & Chen, Q. (2024) · Communications Biology · doi:10.1038/s42003-024-06271-w · Cited by 17
“…α has been shown to facilitate the translocation of Calr from the ER lumen to the cell membrane surface 35 , and recentstudieshaveshownthatanti-cancerdrugspromotetheupregulationof e-IF2 α phosphorylation and IFN β and Cxcl10 expression in tumor cells, whichmayleadtoICD 32,33,35 .”
Cerrato, G., Liu, P., Zhao, L., Petrazzuolo, A., Humeau, J., Schmid, S. T., Abdellatif, M., Sauvat, A., & Kroemer, G. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02189-3 · Cited by 14
Zhou, Z., Guo, F., Zhang, J., Liao, L., Jiang, M., Huang, Y., Liu, Y., Lei, L., Tao, Z., Yu, C., et al. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.01.038 · Cited by 13
Hao, Q., Zhao, W., Li, Z., Lai, Y., Wang, Y., Yang, Q., & Zhang, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117465 · Cited by 14
Liu, G., Zhang, Y., Cao, Z., & Zhao, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02437-5 · Cited by 14
Huang, X., Tang, T., Zhang, G., Hong, Z., Xu, J., Yadav, D. K., Bai, X., & Liang, T. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00136-1 · Cited by 13
Centrosomes and associated proteins in pathogenesis and treatment of breast cancer
Athwal, H., Kochiyanil, A., Bhat, V., Allan, A. L., & Parsyan, A. E. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1370565 · Cited by 11
Lei, J., Chen, J., Chen, J., Fang, J., Zhou, Z., & Xu, A. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150907 · Cited by 14
Wang, B., Tang, X., Xiao, C., Yu, Z., Bo, H., Wang, J., & Wang, J. (2025) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2025.112871 · Cited by 14
Challenges and Opportunities for Effective Cancer Immunotherapies
Slaney, C. Y., & Kershaw, M. H. (2020) · Cancers · doi:10.3390/cancers12113164 · Cited by 11
“For example, anti-PD1 has been tested in combination with CAR T-cell therapy [7], oncolytic virus treatment [8,9], cyclin-dependent kinase inhibitors [10].”
MethodHu, Y., Cai, J., Ye, M., Mou, Q., Zhao, B., Sun, Q., Lou, X., Zhang, H., & Zhao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1037128 · Cited by 10
“A recent study found that ICD improved T-cell responses to different tumors, further enhancing the antitumor immunity of immune checkpoint inhibitors (36).”
BackgroundSchoenwaelder, N., Salewski, I., Engel, N., Krause, M., Schneider, B., Müller, M. K., Riess, C., Lemcke, H., Skorska, A., Große-Thie, C., et al. (2021) · Cancers · doi:10.3390/cancers13102396 · Cited by 12
“also observed apoptosis induction by short-term dinaciclib treatment [33].”
BackgroundYu, Z., Zou, Y., Han, S., Sun, D., Wang, L., Yang, L., Li, Y., Zhang, X., & Guo, J. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.05.013 · Cited by 10
“To study the efficacy of MEL on activating the cGAS-STING pathway in HCC cells for adaptive immune response to living HCC cells of the same kind, the in vivo vaccination assay was carried out as previously described [ 14,17 ].”
Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside
Hassanzadeh, A., Shomali, N., Kamrani, A., Soltani‐Zangbar, M. S., Nasiri, H., & Akbari, M. (2024) · EXCLI journal · doi:10.17179/excli2024-7076 · Cited by 13
Metabolic Inhibition Induces Pyroptosis in Uveal Melanoma
Varney, S. D., Erkes, D. A., Mersky, G. L., Mustafa, M. U., Chua, V. Y. L., Chervoneva, I., Purwin, T. J., Alnemri, E. S., & Aplin, A. E. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0508 · Cited by 12
Dai, W., Xie, D., Huang, H., Li, J., Guo, C., Cao, F., Yang, L., Zhong, C., & Liu, S. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101173 · Cited by 12
“It re-verses the resistance of PARPi and trastuzumab in breast cancer [12,79] and enhances anti-tumor ef fi cacy when combined with anti-PD-1 therapy [99].”
Gong, Z., Jia, Q., Guo, J., Li, C., Xu, S., Jin, Z., Chu, H., Wan, Y. Y., Zhu, B., & Zhou, Y. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00371-1 · Cited by 15
“Strategies aimed at eliciting ICD have been used to overcome resistance to ICB treatments [8].”
BackgroundTeng, C. J., Cheng, P.-T., Cheng, Y.-C., Tsai, J., Chen, M., & Lin, H. (2023) · Toxicology in Vitro · doi:10.1016/j.tiv.2023.105768 · Cited by 9
Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
Chakravorty, S., Zybina, Y., Ahn, E., Pradhan, K., Yu, N., Taylor, M., Charati, M. B., Wilson, D. C., Jeon, A. B., Blumenschein, W. M., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0682 · Cited by 9
Nano Delivery Strategy Opens Effective Avenues for the Treatment of Colorectal Cancer
Wei, Q., Xu, Y., Zhang, T., Xu, S., Wang, H., Wang, Y., Xie, X., & Liang, X. (2026) · Medicine Bulletin · doi:10.1002/mdb2.70028 · Cited by 13
McLeod, R. L., Angagaw, M. H., Baral, T. N., Liu, L., Moniz, R. J., Laskey, J., Hsieh, S., Lee, M., Han, J., Issafras, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26108 · Cited by 8
“We studied the impact of muDX400 at a dose level of 5 mg/kg Q5d as this has been used in many syngeneic mouse tumor models with good efficacy and exposure [25].”
MethodGBP2 condensates promote ferroptosis to sensitize anti-PD-L1 immunotherapy in melanoma
Liu, X., Fang, S., Ren, X., Hong, Y., Guo, J., Liu, X., Gao, L., Nie, H., Ning, Y., Zhang, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67690-9 · Cited by 12
“…micro-environment (TME) remains a major barrier to ef fi cacy, driven by factors such as low expression of immune checkpoints and neoantigens, genomic instability, tumor mutational burden, limited in fi ltration of tumor-in fi ltrating lymphocytes (TILs), and attenuated IFN-γ gene signature 2,3 .”
Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications
Dominguez, E. C., Roleder, C., Ball, B. J., & Danilov, A. V. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2244102 · Cited by 7
“Furthermore, dinaciclib was shown to elicit type I interferon response in colon cancer cells, even following short-term (2 h) exposure, leading to immunologic cell death [97].”
BackgroundJia, D., Zhao, S., Liu, H., Zhan, X., Zhou, Z., Lv, M., Tang, X., Guo, W., Li, H., Sun, L., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132058 · Cited by 9
Nelson, L. J., Castro, K. E., Xu, B., Li, J., Dinh, N. B., Thompson, J. M., Woytash, J., Kipp, K. R., & Razorenova, O. V. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2041783 · Cited by 11
“Importantly, Dinaciclib has been reported to induce immunogenic cell death [33], justifying further in vivo experiments conducted in syngeneic mouse models of CC-RCC [52,53], especially when combining Dinaciclib with immune checkpoint inhibitors, which represent a first-line therapy for CC-RCC [3].”
BackgroundZhao, H., Yang, K., Yue, Z., Chen, Z., Cheng, Z., Sun, H., & Song, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1288492 · Cited by 7
Zhang, L., Wang, I., Solban, N., Cristescu, R., Zeng, G., & Long, B. J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11169 · Cited by 9
“Previous studies from our group and others revealed that the Mc38 tumor model is highly responsive to anti-Pd-1 treatment (19-22). recently, efremova et al (23) demonstrated that the Mc38 cell line is valid for modelling hypermutated/microsatellite-instable (MSi) colorectal cancer (crc). consistent…”
García-Flores, N., Fernández‐Aroca, D. M., Garnés‐García, C., Domínguez‐Calvo, A., Jiménez‐Suárez, J., Sabater, S., Fernández‐Aroca, P., Andrés, I., Cimas, F. J., de Cárcer, G., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13773 · Cited by 8
“Furthermore, our observation may have implications in others therapeutic approaches as immunotherapy in which senescence has recently been shown to be involved [57] and interestingly could explain the effect observed for the combination of dinaciclib and immunotherapy based on anti-PD-1 [58].”
Wang, X., Fang, H., Hu, W., Yuan, F., Zhou, Z., Hu, M., Jiang, D., Zhang, Y., & Lan, X. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03257-6 · Cited by 8
Tatárová, Z., Blumberg, D. C., Bensen, A. L., Mills, G. B., & Jonas, O. H. (2023) · Cells · doi:10.3390/cells12020308 · Cited by 7
“ICD can be induced by chemotherapeutics [12,13], targeted anti-cancer agents [1,14], physical modalities such as radiotherapy [15], oncolytic viruses [16], and gaseous molecules [17].”
BackgroundHu, X., Wang, M., Shi, S., Raja, M. R. K., Gupta, G., Chen, H., & Xu, P. (2023) · Biomaterials Science · doi:10.1039/d3bm00627a · Cited by 6
Lv, G., Hu, X., Zhang, N., Zhu, J., Gao, X., Xi, H., Peng, Y., Xie, Q., Qiu, L., & Lin, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107810 · Cited by 6
Advances in the therapeutic study of oncolytic virus in colorectal cancer
Chen, J., Chen, K., & Yuan, X. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000051 · Cited by 6
Establishing a cryopreserved biobank of living tumor tissues for drug sensitivity testing
Chen, P., Zhou, J., Chu, X., Feng, Y., Zeng, Q., Lei, J.-H., Wong, K.-P., Chan, T.-I., Lam, C.-W., Zhu, W., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.09.008 · Cited by 16
“It has been demonstrated to have clinical activity in refractory chronic lymphocytic leukemia [39 – 43].”
Yang, J. Y., Hu, S., Shangguan, J., Eresen, A., Li, Y., Ma, Q., Yaghmai, V., Benson, A. B., & Zhang, Z. (2020) · PubMed Central · Cited by 9
Zou, B., Jiang, H., Liu, H., Lü, J., Qiang, H., Lu, M., Yu, L., Zhong, H., Chu, T., & Han, B. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300141 · Cited by 11
Zhou, Z.-H., Zhou, X., Zhang, Y., Zhao, T., Li, J., Zhong, L., & Pang, Y. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400012 · Cited by 6
Revisiting immunogenic cell death to improve treatment response in cancer
Shakfa, N., Siemens, D. R., & Koti, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00008-5 · Cited by 6
Roulstone, V., Kyula, J., Wright, J., Patin, E. C., Dean, I., Yu, L., Barreiro-Alonso, A., Melake, M., Choudhary, J. S., Elliott, R. J. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60133-5 · Cited by 6
“ICD has been previously described for single-agent CDK4/6 inhibition 11,12 .”
Li, M., Lin, Y.-T., Wang, J., He, Y., Ma, D., Tian, Y., Wang, Y., Liu, Y., Farooq, U., Wang, Y., et al. (2025) · Theranostics · doi:10.7150/thno.115572 · Cited by 5
“Previous studies have shown that CDK9 inhibition sensitizes tumors to ICB therapy [12, 19].”
Li, Y., Zheng, Z., Xiao, L., Chen, Y., Liu, X., Long, D., Chai, L., Li, Y., & Tan, C. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001545 · Cited by 6
“Thus, the anti-tumor effects of dinaciclib have been restrained [14].”
BackgroundYü, C., Yang, W., Li, T., Qin, Y., Gong, Y., & Cheng, W. (2023) · Open Medicine · doi:10.1515/med-2023-0836 · Cited by 5
“Moreover, studies have found that ICD combined with immune checkpoint inhibitors improves the anti-tumor immune e ff ect [15,16].”
BackgroundSaeed, Y., Zhong, R., & Sun, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111948 · Cited by 6
Xu, Y., Yan, X. W., Zhang, F., Li, Q., Wei, T., Xiao, Z., Chai, Y., Wang, C., & Liu, Z. (2025) · ACS Nano · doi:10.1021/acsnano.5c05354 · Cited by 8
Zhang, H., Chu, T., Zheng, J., Teng, Y., Ma, R., Zou, L., & Zhao, H. (2022) · Medical Oncology · doi:10.1007/s12032-022-01890-x · Cited by 4
“Dinaciclib increases immunogenic cell death and the antitumor activity of an anti-PD1 monoclonal antibody, demonstrating that this drug combination improves antitumor therapy [19].”
BackgroundKinase inhibitors: Opportunities for small molecule anticancer immunotherapies
Safaroghli‐Azar, A., Emadi, F., Lenjisa, J. L., Mekonnen, L. B., & Wang, S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103525 · Cited by 6
Pyroptosis and chemical classification of pyroptotic agents
Hara, M. A., Ramadan, M. A., Abdelhameid, M. K., Taher, E. S., & Mohamed, K. O. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10987-6 · Cited by 4
“Dinaciclib 70 is a selective inhibitor of cyclin-dependent kinases (CDKs), CDK1,2,5,9, used to induce pyroptosis in melanoma through caspase-1/ GSDME/Bax activation [186].”
Fischmann, T. O., Malashock, D., Ahn, E., Wang, H., Pradhan, K., Grein, J., Chakravorty, S., Bahmanjah, S., Ban, D., Chien, E. Y. T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008972 · Cited by 4
Ju, N., Zhao, L., Yin, S., Yang, X., Zhou, J., Gao, J., & Qi, F. (2026) · International Journal of Cancer · doi:10.1002/ijc.70442 · Cited by 6
“…studies have further demonstrated that dinaciclib enhances anti-tumor immunity by inducing immunogenic cell death and potentiates therapeutic effects when combined with Akt inhibition or PD-1 blockade, 67 suggesting dinaci-clib as a potential promising therapeutic target in a clinical setting.”
Nardou, K., Nicolas, M., Kuttler, F., Cisarova, K. V., Çelik, E., Quinodoz, M., Riggi, N., Michielin, O. A., Rivolta, C., Turcatti, G., et al. (2022) · Cancers · doi:10.3390/cancers14061575 · Cited by 5
“Interestingly, the recent demonstration of increased immune infiltrate in xenograft tumor models treated with Dinaciclib and anti-PD1 checkpoint inhibitor along with the interferon type I gene signature induced in vitro by Dinaciclib [68], suggest that the combination of Dinaciclib and anti-PD1 monoclonal antibodies m…”
BackgroundInfluentialRaghavan, S., Shifrin, N. T., Kochel, C. M., Sawant, A., Mello, M., Sathe, M., Blumenschein, W. M., Muise, E. S., Chackerian, A. A., Pinheiro, E. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752348 · Cited by 5
“PD-1 Antibody or Tamoxifen Treatment WT mice were randomized day 7 post-tumor implant, and for PD-1 antibody (Ab) experiments, mice were dosed intraperitoneally every 4 days on four separate occasions with 5 mg/kg antimouse PD-1 Ab muDX400 (16).”
MethodNaylor, G. D., Julian, L., Watson-Bryce, S., Mullin, M., Nibbs, R. J. B., & Olson, M. F. (2022) · Cancers · doi:10.3390/cancers14235943 · Cited by 4
“Furthermore, these results raised Cancers 2022, 14, 5943 3 of 26 the possibility that pharmacological ROCK inhibition could also have similar tumour suppressive effects by inducing ICD.”
BackgroundInfluentialLv, X., Jia, Y., Li, J., Shu, D., & Yuan, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1234181 · Cited by 4
“Dinaciclib is an effective anti-PD1 inhibitor that induces immunogenic cell deaths (Hossain et al., 2018).”
BackgroundChen, Y., Liu, W., Cai, Q., Pan, C., Yin, Z., Tang, Y., He, Z., Cheng, G., & Shu, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1570040 · Cited by 8
Hufnagel, S., Xu, H., Colemam, M. F., Valdes, S. A., Liu, K. A., Hursting, S. D., & Cui, Z. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04367-2 · Cited by 3
Xu, S., Bie, N., Su, X., Zhang, X., Li, S., Liu, H., Yong, T., Chen, Q., Yang, X., & Gan, L. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03635-0 · Cited by 2
“The ICD phenomenon allows DCs to recognize and eliminate apoptotic tumor cells through “eat me” signals such as CRT, thereby promoting T cell-mediated antitumor immunity [49].”
Wang, W., Zhou, L., Zhang, X., & Li, Z. (2025) · Biology Direct · doi:10.1186/s13062-025-00685-0 · Cited by 3
FK228 reshapes tumor microenvironment to enhance anti-PD-L1 efficacy
Gong, L., Tian, L., He, L., Zhou, K., He, H., Xiao, S., Zhu, Y. Z., Gong, Z., Cui, K., & Zhang, Y. (2025) · Oncogene · doi:10.1038/s41388-025-03558-y · Cited by 3
“Tumor tissue slices also showed a signi fi cant increase in the in fi ltration of CD8 + T cells in the FK228-treated group compared with the Ctrl (DMSO treatment) group (Figs.”
InfluentialDighe, S., & Jain, S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104521 · Cited by 3
Roles of CDK12/CDK13 and development of inhibitors and degraders
Li, Z. F., Ke, Y., Zhang, R., Zhang, R., & Zhang, L. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119077 · Cited by 4
Immunogenic Cell Death in Cancer
Humeau, J., Naour, J. L., Kroemer, G., & Pol, J. G. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_121 · Cited by 2
Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors
Chen, B., & Liu, J. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096307629240611104728 · Cited by 2
Repurposing of CDK Inhibitors as Host Targeting Antivirals: A Mini- Review
Liu, M., Peng, W., & Ji, X. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575311618240820103549 · Cited by 2
Liu, Z., Li, W., You, G., Hú, Z., Liu, Y., & Zheng, N. (2023) · Open Medicine · doi:10.1515/med-2023-0716 · Cited by 3
“found that after inducing ICD to kill tumour cells, inoculating dead tumour cells into mice can establish effective immune response and prevent subsequent tumour growth [13].”
BackgroundPD-L1 – PD-1 interactions limit effector Treg cell populations at homeostasis and during infectionPreprint
Perry, J. A., Clark, J. T., Gullicksrud, J. A., DeLong, J. H., Shallberg, L. A., Douglas, B. B., Hart, A. P., Konradt, C., Park, J., Zaretsky, A. G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.09.416990 · Cited by 2
Tatárová, Z., Blumberg, D. C., Korkola, J. E., Heiser, L. M., Muschler, J. L., Schedin, P. J., Ahn, S. W., Mills, G. B., Coussens, L. M., Jonas, O. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.01.458631 · Cited by 2
CDK9 and hematologic malignancies: pioneering novel therapeutic approaches
Raufi, H., Zahmatkesh, P., Safaei, S., Bahadori, A., & Solali, S. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02141-3 · Cited by 1
“These results offer a solid basis for its combination with anti–PD-1 ther - apy [116].”
CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis
Mir, M. A., Sofi, S., & Ishfaq, P. M. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_8 · Cited by 1
Liu, Z., Huang, Y. M., Zhang, P., Yang, C., Wang, Y., Yu, Y., & Xiang, H. (2024) · Aging · doi:10.18632/aging.205647 · Cited by 1
“A combination of ICD inducers and immune checkpoint inhibitors can effectively enhance the antitumor effects, by improving tumor cell immunogenicity and boosting tumor immunotherapy [10–13].”
BackgroundHagbi-Levi, S., Abraham, M., Gamaev, L., Mishalian, I., Hay, O., Zorde-Khevalevsky, E., Wald, O., Wald, H., Olam, D., Weiss, L., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1502094 · Cited by 1
Paramitasari, K. A., & Ishida, Y. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.26.554968 · Cited by 1
“15 MC38 and MCA-205 tumors show different levels of sensitivity to PD-1 deficiency MC38 colon adenocarcinoma cells have been previously reported as an immunogenic cancer cell line with high sensitivity to PD-1/PD-L1 axis blockade (60, 62-67).”
BackgroundNaylor, G. D., Julian, L., Watson-Bryce, S., Mullin, M., Nibbs, R. J. B., & Olson, M. F. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.14.488346
“Some anti65 cancer agents act both by blocking essential targets in tumour cells and by inducing ICD 66 [10].”
BackgroundRoulstone, V., Kyula, J., Wright, J., Yu, L., Barreiro-Alonso, A., Melake, M., Choudhary, J. S., Elliott, R. J. R., Lord, C. J., Mansfield, D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.28.508679
“Peptides belonging to the MAGEA4 protein are highlighted (1-8).”
BackgroundChallenges and Opportunities for Effective Cancer Immunotherapies
Kershaw, M., & Slaney, C. Y. (2023) · MDPI eBooks · doi:10.3390/books978-3-0365-6961-1
Qiu, Z., Zhao, L., Shen, J., Liang, Z., Wu, Q., Yang, K., Min, L., Gimple, R. C., Yang, Q., Bhargava, S., et al. (2023) · doi:10.1158/2159-8290.22541297
Li, H., Liu, J., Jiang, Y., Chen, A., Wang, L., & Huang, H. (2023) · Research Square · doi:10.21203/rs.3.rs-3810345/v1
García-Flores, N., Fernández‐Aroca, D. M., Garnés‐García, C., Domínguez‐Calvo, A., Sabater, S., Andrés, I., Jiménez‐Suárez, J., Fernández‐Aroca, P., Cimas, F. J., de Cárcer, G., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.25.590582
Luján-Méndez, F., García‐López, P., Berumen, L. C., García‐Alcocer, G., Ferriz‐Martínez, R. A., Ramírez-Carrera, A., González-Barrón, J., & García-Gasca, T. (2025) · Pharmaceuticals · doi:10.3390/ph18020213
“…− (T t − T 0 )] / (C t − C 0 ) × 100 where C t was the mean tumor volume in the control group at time ( t ); C 0 was the mean tumor volume in the control group at t 0 ; T t was the mean tumor volume in the treatment group at t ; and T 0 was the mean tumor volume in the treatment group at t 0 [82].”
Metadata
- Authors
- Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., & Chackerian, A.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Chackerian, Alissa
- Venue
- Journal of Clinical Investigation
- Published
- 2018-01-16
- Volume
- 128
- Issue
- 2
- Pages
- 644-654
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5785250
- OpenAlex
- W2783507731
- Cited by
- 216
- References
- 88
- Citations by year
- 2026: 11 · 2025: 25 · 2024: 37 · 2023: 45 · 2022: 29 · 2021: 22 · 2020: 32 · 2019: 11 · 2018: 4
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- dinaciclib, immunogenic cell death, anti-PD-1 therapy, combination cancer immunotherapy, cyclin-dependent kinase inhibitors, type I interferon signature, calreticulin, HMGB1, ATP release, T cell infiltration, tumor immunogenicity, cancer vaccines
- MeSH terms
- Adenocarcinoma, Adenosine Triphosphate, Animals, Antibodies, Monoclonal, Cyclic N-Oxides, Dendritic Cells, Drug Synergism, Female, Immune System, Immunotherapy, Indolizines, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasm Transplantation, Phagocytosis, Pyridinium Compounds, Cytokines, Cell Death, Apoptosis, Mice, Knockout, CD8-Positive T-Lymphocytes, Bridged Bicyclo Compounds, Heterocyclic, HMGB1 Protein, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.